New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine

Depression and Anxiety

Volumn 7, Issue SUPPL. 1, 1998, Pages 24-32

  Owen, J Randall ^a   Nemeroff, Charles B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug interactions; Mirtazapine; Nefazodone; P450; Venlafaxine

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CISAPRIDE; CYTOCHROME P450; DEXTROMETHORPHAN; DIAZEPAM; DIGOXIN; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; ISOENZYME; KETOCONAZOLE; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; RISPERIDONE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; THEOPHYLLINE; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; GENE; HEART ARRHYTHMIA; HUMAN; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CYCLOHEXANOLS; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER; HUMANS; ISOENZYMES; MIANSERIN; RISK FACTORS; TRIAZOLES;

EID: 0031959635     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6394(1998)7:1+<24::AID-DA7>3.0.CO;2-F     Document Type: Article

References (40)

1. Amchin J, Ereshefsky L, Zarycranski WM (1997a) Effect of venlafaxine versus fluoxetine on the metabolism of dextromethorphan, a CYP2D6 marker. Presented at the 149th Annual Meeting of the American Psychiatric Association, San Diego, CA; May 1997.
2. Amchin JD, Zarycranski W (1996) Effect of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 32:410.
3. Amchin JD, Zarycranski W, Taylor K (1997b) Effect of venlafaxine on the pharmacokinetics of risperidone. Presented at the 37th Annual New Clinical Drug Evaluation Unit Program, Boca Raton, Florida; May 1997.
4. Amchin J, Zarycranski W, Taylor K. (1997c) Evidence that venlafaxine does not inhibit CYP1A2 as measured in vivo by the metabolism of caffeine. Presented at the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA; March 5-8, 1997.
5. Amchin JD, Zarycranski W, Taylor K (1997d) Venlafaxine's lack of CYP3A4 inhibition is further confirmed by an in vivo study with terfenadine. Presented at the 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Diego, CA; March 5-8, 1997.
6. Ashton AK, Wolin RE (1996) Nefazodone-induced carbamazepine toxicity [letter]. Am J Psychiatry 153:733.
7. Ball SE, Ahern D, Scantina J, Kao J (1997) Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRI's, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br J Clin Pharmacol 43:619-626.
8. Barbhaiya RH, Buck AB, Greene DS (1996a) Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. Br J Clin Pharmacol 42:573-581.
9. Barbhaiya RH, Shukla UA, Greene DS (1995a) Lack of interaction between nefazodone and cimetidine: A steady-state pharmacokinetic study in humans. Br J Clin Pharmacol 40:161-165.
10. Barbhaiya RH, Shukla UA, Greene D, Brenel HP, Midha KK (1996b) Investigation of pharmacokinetic and pharmacodynamic interaction after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol 16:26-34.
11. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS (1995b) Coadministration of nefazodone and benzodiazepine: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15:320-326.
12. Dahl ML, Voortman G, Alm C, Elwin CE, Delbressine L, Vos R, Bogarrds JJP, Bertilsson L (1997) In vitro and in vivo studies on die disposition of mirtazapine in humans. Clin Drug Invest 13:37-46.
13. Davis R, Whittington R, Bryson HM (1997) Nefazodone: A review of its pharmacology and clinical efficiency in the management of major depression. Drugs 53:608-636.
14. Delbressine LPC, Vos RME (1997) The clinical relevance of preclinical data: Mirtazapine, a model compound. J Clin Psychopharmacol 17(suppl 1):29S-33S.
15. Dockens RC, Greene DS, Barbhaiya RH (1996) Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol 36:160-167.
16. Dockens RC, Rapoport D, Roberts D, Greene DS, Barbhaiya RH (1995) Lack of an effect of nefazodone on the pharmacokinetics and pharmacodynamics of theophylline during concurrent administration in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol 40:598-601.
17. Eaton DL, Gallagher EP, Bammler TK, Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: Implications for human variability in expression and enzyme activity. Pharmcogenetics 5:259-274.
18. Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism: Clinical aspects. Pharmacol Ther 46:377-394.
19. Ereshefsky L (1996) Drug-drug interactions involving antidepressants: Focus on venlafaxine. J Clin Psychopharmacol 16(suppl 2):37S-50S.
20. Ereshefsky L, Overman GP, Karp JK (1996) The 1996 Black Book of Psychotropic Dosing and Monitoring. New York: MBL Communications, pp 14-15.
21. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995a) Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15:399-408.
22. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995b) Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam. J Clin Psychopharmacol 15:409-416.
23. Howell SR Husbands GEM, Scantina JA, Sisenwine SF (1993) Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus moneky, and man. Xenobiotica 23:349-359.
24. Kroboth PD, Folan MM, Lush RM, Chaikin PC, Shukla UA, Barbhaiya R, Salazar DE (1995) Coadmmistration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. J Clin Pharmacol 15:306-319.
25. Kroemer HK, Eichelbaum M. (1995) "It's the genes, stupid": Molecular basis and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298.
26. Lam YWF, Alfaro C, Ereshevsky L, Amchin J (1997) Cross-over comparison of CYP2D6 inhibition. Insignificant effect of venlafaxine compared to scrtralinc, paroxetine, and fluoxetine. Presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego, CA; May 1997.
27. Marino MR, Langenbacher KM, Hammett JL, Nichola P, Uderman HD (1997) The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. J Clin Psychopharmacol 17:28-33.
28. Medical Economics (1997a) Physician's Desk Reference, 51st ed. Montvale, NJ: Medical Economics, pp 776-779 (nefazodone).
29. Medical Economics (1997b) Physician's Desk Reference, 51st ed. Montvale, NJ: Medical Economics, pp. 935-940 (fluoxetine).
30. Medical Economics (1997c) Physician's Desk Reference, 51st ed. Montvale, NJ: Medical Economics, pp 2723-2727 (fluvoxamine).
31. Nemeroff CB, DeVane CL, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311-320.
32. Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br J Clin Pharmacol 41:149-156.
33. Richelson E (1997) Pharmacokinetic drug interactions of new antidepressants: A review of the effects on the metabolism of other drugs. Mayo Clin Proc 72:835-847.
34. Salazar DE, Dockens RC, Milbrath RL, Raymond RH, Fulmor E, Chaikin PC, Uderman HD (1995) Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 35:730-738.
35. Salazar DE, Marathe PH, Fulmor IE, Lee JS, Raymond RH, Uderman HD (1995) Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. J Clin Pharmacol 35:1109-1118.
36. Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI (1996) Inhibition of cytochrome P450 by nefazodone in vitro: Studies of dextromethorphan O- and N-demethylation. Br J Clin Pharmacol 41:339-343.
37. Troy SM, Lucki I, Peirgies AA, Parker VD, Klockowski PM, Chiang ST (1995) Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 35:410-419.
38. von Moltke LL, Duam SX, Greenblatt DJ, Fogelman SM, Schmider J, Harmatz JS, Shader RI (1997) Venlafaxine and metabolites are weak inhibitiors of human cytochrome P450-3A isoforms. Biol Psychiatry 41:377-380.
39. von Moltke LL, Greenblatt DJ, Duam SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996) Phenacetin Odeethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 128:398-407.
40. Wyeth-Ayerst Laboratories, Inc. (1997) Effexor XR (venlafaxine hydrochloride)(package insert). Philadelphia, PA: Wyeth-Ayerst Laboratories, Inc.